Really solid 4C - the cash receipts were slightly lower than I expected ($1,478K versus my estimate of $1,600K), but the expenses were way down on my estimates ($2,388K versus estimate of $3,400K).
The last 4 x cash outgoings (total expenses) on the 4C's have been approximately:
31/12/18 $4,056k
31/3/19 $3,635k
30/6/19 $3,555K
30/9/19 $2,388k
There was a huge decrease in cash outgoings in the last quarter - so they are obviously "tightening their belts" due to the delay in the approvals.
Cash burn of less than $1.0m this quarter (when it has always been from $2.2m to $2.7m) - reducing the nett cash outgoings will help a lot going forward.
@ JG22 - surely you jest about complaining to the ASX? The 4C was on time!!, and I am sure we will get an update on the US & UK markets at some point.
IMO GMV management really need some "clean air" now to finalise some deals, and make sure we get the approvals required ASAP.
Am quietly confident that the market will like this 4C.
- Forums
- ASX - By Stock
- GMV
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-17
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online